On Demand, On Purpose: Fashion Manufacturing That Doesn’t Cost the Earth
Daily Compliance News: July 16, 2025, The Corruption Comes to Cannes’ Edition
Understanding Human Trafficking and Modern Slavery: A Business Imperative with Clint Palermo
PODCAST: Williams Mullen's Benefits Companion - Navigating Fiduciary Responsibilities in a Tide-Turning ESG Era
ESG Essentials: What You Need To Know Now - Episode 18 - The Reshaping of ESG & DEI
Compliance into the Weeds: More Compliance Challenges in the Trump Era
Podcast — UK FinReg Focus Areas in 2025: Sectoral Trends
Environmental and Sustainability Regulations & the New Administration
Podcast - Beyond Compliance: A Deep Dive into Carbon Markets Fraud and the Government's Response
ESG Essentials: What You Need To Know Now - Episode 17 - The Evolution of ESG Enforcement Under the SEC
Navigating ESG: Preparing for Future Regulations (Part Two) — Regulatory Oversight Podcast
Regulatory Uncertainty: Benefits-Related Legal Challenges in a Post-Chevron World — Troutman Pepper Podcast
Navigating ESG: The Growing Importance and Compliance Challenges (Part One) — Regulatory Oversight Podcast
AGG Talks: Cross-Border Business Podcast - Episode 16: The Political and Legal Maze of ESG in the U.S. and Abroad
Episode 326 -- Dottie Schindlinger on Diligent's Report on Board Oversight of Cybersecurity Risks and Performance
Why ESG Matters?
JONES DAY TALKS®: ESG Reporting Rules: The SEC, CSRD, and California– Who's on the Hook?
ESG Masterclass — Legal Risks Hiding in Your DEIB Programming
Leaning in on AI in Compliance Programs
ESG Masterclass — ESG and Impact Investing
Deal activity: Deal count has picked up through the first half of 2025, up 2% compared to the same period last year but still down 7% from H2 2024. With geopolitical tensions, investors and analysts alike are forecasting...more
Meanwhile, cash-strapped biotechs have in many cases been forced to leverage relationships with big pharma to address liquidity. Cash is king in a financing environment such as we have observed over the last 18 months, and...more
There is a wealth of dry powder to spend but 2023 has seen M&A deal activity hampered by rising costs of debt, unstable markets, supply chain issues, general political uncertainty, and fear of global recession. So, what does...more
After an insightful conference in Cannes, our partners have compiled some of the key takeaways from IPEM 2022. As well as exploring the private equity landscape in the UK, Germany, France and Italy, we also explore the...more
As the world enters a phase of the global pandemic marked by an increasing rate of vaccinations, investors are looking for global (particularly, European) healthcare market opportunities. With the emergence of certain...more
After a year during which uncertainty in the equity markets became the new normal, many stakeholders are wondering whether the disruptions are behind us. A look at key indicators might lead one to say yes. The S&P Loan Index...more